

*REVIEW Article*

## Bacterial RNA as a signal to eukaryotic cells as part of the infection process

Denis Simonov,<sup>1,2</sup> Simon Swift,<sup>1,\*</sup> Cherie Blenkiron,<sup>1,2</sup> Anthony R. Phillips<sup>2,3,4</sup>

<sup>1</sup>Department of Molecular Medicine and Pathology, <sup>2</sup>Department of Surgery, <sup>3</sup>School of Biological Sciences, and <sup>4</sup>Maurice Wilkins Centre, University of Auckland, Auckland, New Zealand;

\*Corresponding author: Simon Swift, PhD, Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Private Bag 92019, Auckland 1142, New Zealand. Phone: +64 9 373 7599 ext 86273; E-mail: s.swift@auckland.ac.nz

Submitted: Dec. 27, 2016; Revised: Dec. 31, 2016; Accepted: Dec. 31, 2016; Published: Dec.31, 2016;

Citation: Simonov D, Swift S, Blenkiron C, Phillips AR. Bacterial RNA as a signal to eukaryotic cells as part of the infection process. *Discoveries* 2016, Oct-Dec; 4(4): e70. DOI: 10.15190/d.2016.17

### ABSTRACT

The discovery of regulatory RNA has identified an underappreciated area for microbial subversion of the host. There is increasing evidence that RNA can be delivered from bacteria to host cells associated with membrane vesicles or by direct release from intracellular bacteria. Once inside the host cell, RNA can act by activating sequence-independent receptors of the innate immune system, where recent findings suggest this can be more than simple pathogen detection, and may contribute to the subversion of immune responses. Sequence specific effects are also being proposed, with examples from nematode, plant and human models providing support for the proposition that bacteria-to-human RNA signaling and the subversion of host gene expression may occur.

### Keywords:

Regulatory RNA, cross-kingdom communication, pathogenicity, innate immunity, RNAi, membrane vesicles.

### Abbreviations:

Adenosine triphosphate (ATP); apoptosis-associated speck-like protein containing a CARD (ASC); argonaute (AGO); caspase recruitment domain (CARD); conventional dendritic cell (cDC); cyclic adenosine monophosphate (cAMP); deoxyribonucleic acid (DNA); double stranded RNA (dsRNA); N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl sulfate (DOTAP); dual

specificity mitogen-activated protein kinase kinase 4 (MAP2K4); dual oxidase 2 (Duox2); 5-ethynyluridine (5EU); interferon (IFN); Interferon regulatory factors (IRFs); interleukin (IL); lipopolysaccharide (LPS); Melanoma Differentiation-Associated protein 5 (MDA5); membrane vesicle (MV); messenger RNA (mRNA); microRNA (miRNA); mitogen activated protein kinase (MAPK); Mitogen-activated protein kinase kinase kinase 7 (MAP3K7); NADPH oxidase 1 (NOX-1); nicotinamide adenine dinucleotide phosphate (NADPH); NLR family, pyrin domain containing (NLRP3); Nod-like receptor X-1 (NLRX-1); nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB); NF-κB inhibitor-like protein 1 (NFKBIL1); pathogen associated molecular pattern (PAMP); polyinosinic:polycytidylic acid (poly I:C); reactive oxygen species (ROS); Receptor-type tyrosine-protein phosphatase eta (PTPRJ); retinoic acid-inducible gene I (RIG-I); ribonuclease (RNase); ribonucleic acid (RNA); RNA interference (RNAi); ribosomal RNA (rRNA); single stranded RNA (ssRNA); small RNA (sRNA); T-helper (Th); TIR-domain-containing adapter-inducing interferon-β (TRIF); toll-like receptor (TLR); transfer RNA (tRNA); tumour necrosis factor (TNF).

### SUMMARY

1. Introduction
2. Bacterial RNA in the extra- and intra-cellular environment of human cells
3. Interactions of bacterial RNA with the innate immune system
4. Sequence-specific action of bacterial RNA in host cells
5. Conclusions

## 1. Introduction

Cells do not exist in isolation and so cell-to-cell signaling is important in all biological systems; be it a simple community of single-celled organisms or a multicellular organism coordinating information flow between its own cells and those of its microbiota. Through the course of evolution multiple “languages” have been developed for communications between cells that utilize most, if not all, key biomolecules for intracellular and intercellular signaling pathways: proteins, lipids, carbohydrates, and small organic and inorganic molecules. For humans, an important interface is manifested in the cellular and molecular interactions with microorganisms such as both pathogens and symbionts. It is therefore not surprising that these diverse species have evolved mechanisms for interpreting and manipulating the various signaling systems of the other, giving rise to the phenomenon of cross-kingdom communication.


Perhaps our first appreciation of cross-kingdom communication came from the investigation of the molecular mechanisms of bacterial protein virulence factors. The cholera toxin provides a simple example whereby this protein hijacks key intracellular signaling through the second messenger cAMP<sup>1</sup>, leading to a profuse acute diarrhea that is hypothesized to help disseminate the pathogen. A more complex “conversation” has been described between *Salmonella* and its target cells, where the protein effectors delivered by type 3 secretion are primarily responsible for invasion, as well as niche maintenance and dampening of immune responses<sup>2</sup>. The discovery that bacterial cells communicated to one another via a range of small molecule signals, such as acylated homoserine lactones, in a process termed “quorum sensing” highlighted the possibility that cross-kingdom communication could use a non-protein language<sup>3, 4</sup>, confirmed by the finding that the quorum sensing signals used by bacteria to coordinate their pathogenic activities could also influence immune responses to the pathogen<sup>5, 6</sup>.

Moreover, communication is not only from bacterium to target cell, as gene expression is also influenced in bacteria that can intercept intercellular signals deriving from human cells<sup>7</sup>.

Most recently evidence has emerged for a new “language” for communication between host and bacteria that is based on the identification of regulatory RNAs in both prokaryotes and eukaryotes. Our appreciation of the potential roles of RNA is now going beyond the classical designations of messenger, ribosomal and transfer RNAs in the mechanics of translation. Studies have demonstrated that the manipulation of this “riboregulation” is central to the molecular pathogenicity of some viruses<sup>8,9</sup>, and highlighted the hitherto underappreciated role that the subversion of regulatory RNAs could play in progressing infections. The discovery of microRNA (miRNA) signals produced by one cell to influence gene expression in another<sup>10</sup> has demonstrated RNA as a language of inter-cellular communication identifying them as a potential target for bacterial pathogens.

Today, bacterial RNA is well recognized as an important “pathogen associated molecular pattern” (PAMP) that is involved in human responses to infection. This has been coupled with an appreciation that bacterial RNA is not just a simple uniform trigger of the non-specific immune system, but rather a complex multifaceted signal. For example the differential availability of RNA-recognizing sensors in the host, differences in their subcellular localization and the need to differentiate between ‘self’ and ‘foreign’ RNA define a complex ability of the host to detect intruding RNA and mount a defensive response<sup>11</sup>. In parallel, bacteria can deliver their RNA to the host, for example, using membrane vesicles (MVs) that may protect their cargo while delivering to specific compartments of the host cell<sup>12, 13</sup>. In this review, we discuss the current understanding of the role of RNA in human/bacteria interactions (as summarized in Figure 1) and provide an outlook for future developments of the field.

- ◆ Bacterial RNA can be delivered to human cells during infection
- ◆ Bacterial RNA can have effects beyond simple sensing as a pathogen danger signal
- ◆ Bacterial RNA can act in sequence-independent and sequence-dependent mechanisms



**Figure 1. Interactions of bacterial RNA with an eukaryotic host cell.** a) Entry of bacterial RNA (blue shaded area): Bacterial RNA in double and single stranded forms (red) of extracellular bacteria (green) can enter human cells with MVs, whilst intracellular bacteria can secrete RNA into phagosomes and the cytosol. Bacterial RNA can translocate from phagosomes into the cytosol due to the inherent leakiness of phagosome or when bacterial pore-forming toxins (green stars) disrupt integrity of phagosomes. b) Interactions with the innate immune system (red shaded area): In the endosome, bacterial RNA is sensed by TLR3, TLR7, and TLR8, whilst in the cytosol DExD/H motif helicases such as MDA5 and RIG-I and the NLRP3 inflammasome (via a yet unknown intermediate RNA helicase) can interact with bacterial RNA to trigger downstream signaling cascades. c) Modulation of host cell by bacterial RNA (grey-shaded area): Engagement of innate immune system RNA sensors leads to expression and secretion of type I and type III interferons as well as NF- $\kappa$ B-controlled cytokines which can skew the immune system away from antibacterial response and promote bacterial colonization and dissemination. Activation of the NLRP3 inflammasome leads to Caspase 1 mediated cleavage of pro-IL-1 $\beta$  into active IL-1 $\beta$ . It is postulated that bacterial RNA may also exert post-transcriptional control of human gene expression via sequence-specific interactions with host RNAs. Please refer to the main article for more details and definitions of the abbreviations used.

## 2. Bacterial RNA in the extra- and intra-cellular environment of human cells

RNA is abundant and a lysed bacterial cell will release about tenfold more RNA than DNA<sup>14, 15</sup>. The cells of mucosal barriers and infected tissues will therefore be regularly exposed to RNA from lysed bacteria and other microorganisms. Human tissues and fluids<sup>16-19</sup> contain high levels of RNases, in the order of several hundred nanograms per milliliter<sup>20, 21</sup>, that would be expected to degrade this RNA<sup>22</sup>. However, host miRNA bound to proteins, lipids and lipoproteins is known to be protected from the

external RNases<sup>23</sup>, with the secondary and tertiary structure of some RNA molecules also likely to provide protection from degradation<sup>24</sup>. More recently, advances in small RNA sequencing technology have allowed a detailed analysis of circulating RNAs in mammalian blood, identifying a surprisingly large proportion (ranging from 0.31-11%) as microbial RNA<sup>25, 29</sup>. It is therefore probable that some RNA released following bacterial cell death will remain in the immediate environment of the human host.

In addition to the RNA released from lysed bacterial cells, detectable levels of RNA have been

reported to be present in supernatants from cultures where most bacteria are viable<sup>30-32</sup>, suggesting that active secretion of RNA may also be at play. Indeed, extracellular RNA from these bacterial populations has been found associated with MVs<sup>12, 31, 33-35</sup>, as well as in a 'free' form<sup>31</sup>. The nano-sized MVs are produced by both gram-positive<sup>36</sup> and gram-negative bacteria<sup>37</sup> growing in biofilms, planktonic cultures, inside eukaryotic cells and under a variety of other environmental conditions<sup>38-40</sup>. In many respects, such as size and types of carried molecular cargo, MVs are similar to human exosomes<sup>34</sup>. Human exosomes have a well-established role in RNA communication<sup>41-43</sup>, predominantly through their carriage of regulatory miRNAs, and a similar role for bacterial MVs is beginning to emerge in the literature<sup>12, 13</sup>. MVs, like exosomes, protect RNA from degradation as shown by comparisons following RNase treatment of MVs<sup>12</sup>. The specific protein or other factors that improve the stability of MV-free bacterial RNA are yet to be determined.

A growing body of work is now available to support various mechanisms of outer membrane vesicle production by Gram-negative bacteria that involve budding from the outer membrane, induction by stress responses and some selectivity in the composition of the MV cargo<sup>44-46</sup>. An alternative mechanism for the formation of MVs via explosive cell lysis has recently been identified for *Pseudomonas aeruginosa*<sup>35</sup>. Strains that encode a prophage endolysin (A0629) can undergo an explosive cell lysis event in response to exogenous stress and produce MVs through vesicularization of membrane fragments. This process allows capture of cellular components released into the extracellular space, including the incorporation of RNA into the MVs. It is yet to be determined if explosive cell lysis under non-stress conditions is a programmed cell death pathway induced by "altruistic suicide"<sup>47</sup> to release key nutrients to other bacteria as a "colony public good", or if it is the result of stochastic expression of the A0629 endolysin or if it could be part of a regulated virulence program. It will be of interest to determine if this process occurs in other species of bacteria, as genes with high similarity to A0629 can be found in the genomes of several other bacterial genera<sup>35</sup>.

Free RNA added to the medium of cultured cells can induce responses that favour bacterial colonization and immune evasion<sup>32</sup>. However, the relevance of this role in an infective setting is

unclear as RNA released from bacteria into the extracellular environment probably has a long way to travel before it can influence the activity of host cells. Mechanisms of bacterial MV entry into host cells have been widely studied<sup>48-56</sup>, although it has not yet been shown which mechanism(s) are involved in the uptake of RNA-carrying MVs. Bacterial MVs are a heterogeneous population and we speculate that RNA-carrying MVs may represent only a fraction of the total MV population. At the same time, the mechanism of host entry by a bacterial MV, and consequently the targeting and fate of its cargo, is likely to be different for various MV subpopulations and influenced by MV size, surface molecules etc. In cases where the intracellular delivery of bacterial RNA has been studied, the evidence obtained currently suggests it is necessary for the induction of responses associated with exogenous RNA sensing<sup>57, 58</sup> (discussed in the section "Interactions of bacterial RNA with the immune system" below).

An alternative route for bacterial RNA to enter human cells is via release from intracellular bacteria. *Listeria monocytogenes* is a model organism for the study of intracellular bacteria/host interactions<sup>59</sup>. When the RNA of live *L. monocytogenes* was labelled with a modified nucleotide, 5-ethynyluridine (5EU), and these bacteria were allowed to infect the human monocytic cell line THP-1 the visualization of bacterial RNA by chemically attaching a fluorophore to the 5EU-RNA revealed it in an extra-bacterial localization in the host cell cytosol<sup>60</sup>. Further, no evidence of cytoplasmic, extra-bacterial RNA was found for THP-1 cells infected with 5EU-labelled *L. monocytogenes* lacking the SecA2 auxiliary protein secretion system<sup>53</sup>, suggesting that the bacterial RNA is actively secreted, possibly in association with a protein chaperone, rather than being a by-product of bacterial lysis.

In a related report, RNA released from bacteria that themselves remain trapped in the phagosome can also exert an effect. In the case of *Borrelia burgdorferi*, this occurs via RNA interaction with the endosomal TLR8 to induce transcription of IFN- $\beta$ <sup>61</sup>. In other instances, RNA from the phagocytosed bacteria can translocate into the cytosol from phagosomes that are intrinsically leaky<sup>62</sup>, or made leaky by the actions of bacterial pore-forming toxins<sup>63</sup>.

Overall, the reported findings from the last several years demonstrate that bacterial RNA is a common component in the environment of many human cells. Additionally, current evidence suggests that release of RNA by bacteria is not a simple by-product of bacterial cell death, but an active, and possibly, selective process. The variety of mechanisms involved in the secretion of RNA from bacterial cells, its stability in host extracellular fluids, its association with transport systems for intra- and inter-species signaling such as MVs, and its secretion into host intracellular compartments by live intracellular bacteria suggest that RNA may be used by bacteria as a currently underappreciated virulence factor. Which pathways are engaged by bacterial RNA will likely depend at least in part, on where inside a human cell bacterial RNA is delivered. Evidence to date suggests that bacterial RNA can be delivered into human cytosol<sup>30, 59, 64, 65</sup>, endosomal and phagosomal compartments<sup>66, 67</sup> with one study reporting delivery of bacterial MV RNA into human cell nuclei<sup>13</sup>. Thus, current research has focused on the interactions of bacterial RNA with cytosolic and endosomal receptors of the innate immune system and on the investigation of possibilities for bacterial RNA to affect human gene expression via post-transcriptional mechanisms in a sequence-dependent manner. Key recent discoveries from each of these fields are discussed in the following sections of this review.

### 3. Interactions of bacterial RNA with the innate immune system

Entry of bacterial RNA into a host eukaryotic cells is sensed as a danger signal by receptors of the innate immune system. In the endosome, RNA can be recognized by TLR3, TLR7, and TLR8. TLR3 senses long (>39bp) double stranded RNA (dsRNA)<sup>68</sup>, while TLR7 and TLR8 sense degradation products of single stranded RNA (ssRNA). All three TLRs recognize RNA in a sequence-independent manner, although there is some evidence for preferential recognition of RNA rich in some nucleotides or modified nucleotides<sup>69, 70</sup>. It has been proposed this relates to the observation that some pathogens display a greater proportion of certain types of nucleotides in their RNA sequences<sup>71</sup>. Furthermore, for at least TLR8, the key descriptors for RNA recognition are not yet certain, as THP-1 cells (a cultured monocyte line)

challenged with enterococcal RNA only responded (measured as IL-12 production) when 23S and 16S rRNA, but not when mRNA, were applied<sup>72</sup>.

In the cytosol, some of the key sensors of bacterial RNA are two helicases of the DExD/H motif family, namely RIG-I and MDA5, which detect 5' triphosphorylated short dsRNA and long dsRNA, respectively<sup>73</sup>. RIG-I binds blunt ends of dsRNA displaying a 5' triphosphate moiety whilst MDA5 molecules bind RNA independently of its terminal structures. Additionally, the NLRP3 (NLR family, pyrin domain-containing) inflammasome has recently emerged as an important cytosolic sensor of bacterial RNA<sup>57, 74, 75</sup>. It is a signaling complex that consists of the sensor molecule NLRP3, the adaptor protein ASC and caspase 1, which, in addition to bacterial RNA, senses a variety of endogenous and pathogen-associated molecules (pore-forming cytotoxins, ATP, uric acid<sup>76</sup>).

Induction of the innate immune sensors for bacterial RNA can lead to secretion of type I and type III interferons, and pro-inflammatory cytokines such as TNF- $\alpha$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-6, IL-8, IL-10, and IL-12<sup>14, 15, 32, 58, 59, 61, 72, 77-82</sup>. However, which RNA sensors are engaged and what host effector molecules are secreted is cell type specific. For example, IFN- $\alpha$  secretion is induced in murine plasmacytoid dendritic cells upon DOTAP-mediated transfection of *Escherichia coli* RNA but not in conventional dendritic cells (cDCs)<sup>80</sup>. IFN- $\beta$  is secreted by murine cDCs in response to transfection with RNA from Group B<sup>15</sup> and Group A streptococci<sup>78</sup>. However, in bone marrow-derived macrophages IFN- $\beta$  only responded to transfection of DNA, and not RNA, of Group A streptococci. These differences in responses to bacterial RNA reflect differential availability and use of molecular RNA sensors in different cell types. Differences in host cell responses to the type of RNA (tRNA, rRNA, mRNA etc) can also reflect variations in post-transcriptional modifications of a given prokaryotic RNA molecule across various species<sup>80, 83-85</sup>. For example, when polyadenylated, prokaryotic mRNAs have a shorter poly-A tail than their eukaryotic host mRNAs, and as such can be readily detected by TLR7<sup>69</sup>. Additionally, the 2'-O-methyl guanosine modification status of tRNA at the conserved G18 residue can determine TLR7 activation. For some pathogenic bacteria, where G18 is unmodified, the induction of type I interferon and pro-inflammatory cytokines is seen in mouse

dendritic and human peripheral blood mononuclear cells, whilst modified tRNA from non-pathogenic *E. coli* Nissle 1917 and *Thermus thermophilus* does not<sup>86</sup>. Finally, the cellular localization of the pathogen (cytosolic or phagolysosomal for instance) determines which sensors of bacterial RNA are engaged<sup>11, 22</sup>.

Studies of innate immune responses to bacterial RNA have mostly focused on the identification of host cell receptors for bacterial RNA and downstream signaling cascades. Minimal research has been done to investigate how bacteria could use their RNA to manipulate innate immunity to their advantage. Notably, many of the effector molecules secreted by host cells in response to detection of bacterial RNA are also secreted in response to viral RNA. In fact, the RNA sensors discussed above were originally discovered as sensors of viral infections. In the last decade they have also been validated as sensors of bacterial RNA<sup>74, 80, 87</sup>. Studies of secondary bacterial infections that develop as a complication of viral infections, could therefore provide some insights into the relevance of RNA-induced cytokines on the progression of bacterial infections. Interestingly, it has been observed that, although common host mediators are induced, antiviral and antibacterial responses can frequently be at odds with one another<sup>88</sup>. This provides an opportunity to speculate that bacteria might use interactions of its secreted RNA with host innate immune sensors to its advantage by skewing the immune system towards antiviral responses. In evolutionary terms, it is possible to imagine how such a mechanism for manipulating the human host could have evolved in bacteria. The human microbiome includes not only bacteria but multiple other types of organisms including viruses, fungi and protozoa<sup>89</sup>. Bacteria/human cross-kingdom interactions are, therefore, a product of dynamic coevolved relationship between the various organism of the microbiome and the immune system. It is therefore possible that bacteria might have evolved to utilize elements of human/virus interaction to their advantage even in the absence of viral co-infection. In this case, we hypothesize that the secretion of bacterial RNA and its detection by human cells could create a beneficial environment for bacteria, similar to that of viral-bacterial co-infection.

The strongest evidence for the beneficial effects of RNA-induced cytokines on a bacterial infection

process comes from studies of type I interferons. Whilst induction of type I interferons can lead to host protection and elimination of the pathogen during infections with *Chlamydia trachomatis*<sup>90</sup>, *Salmonella enterica*<sup>91</sup>, *Cryptococcus neoformans*<sup>92</sup>, Group B streptococci, *Streptococcus pneumoniae* and *E. coli*<sup>93</sup>, there is evidence that indicates that type I interferons can also inhibit host defense against other bacteria<sup>94, 95</sup>. For example, pathogen-induced production of type I interferons has been suggested to contribute to the pathogenesis of *Mycobacterium tuberculosis* infections<sup>96</sup>, and the dissemination of *B. burgdorferi* during the early stages of infection<sup>97</sup> where TLR7-dependent recognition of *B. burgdorferi* RNA is necessary for interferon- $\alpha$  production<sup>77</sup>.

Evidence that bacteria could benefit from interferon-induced skewing of the innate immunity towards antiviral responses also comes from investigations of the activation of T helper 17 (Th17) cells. The Th17 pathway has a critical role during infection with extracellular bacteria<sup>98</sup>. IL-17 and IL-22 are hallmark cytokines of Th17 cells, and have been shown to promote clearance of bacteria through the recruitment of phagocytes and the induction of antimicrobial peptides (AMPs)<sup>99</sup>. Induction of type I interferon production by epithelial cells in response to viral infections skews the immune status towards an antiviral phenotype and attenuates type 17 immunity against such bacterial pathogens as *E. coli* and *P. aeruginosa*<sup>100</sup>, *S. aureus*<sup>101</sup> and *S. pneumoniae*<sup>102</sup>. The identification of bacterial communications that direct immune responses away from antibacterial activity have also been a reported feature of the response to some bacterial quorum sensing signals<sup>5</sup>.

Interactions of bacterial RNA with innate immune sensors could also serve a beneficial function to bacteria via mechanisms not involving interferon signaling. Transfection of bacterial RNA has been shown to induce reactive oxygen species (ROS) production via mechanisms involving NADPH oxidase and the mitochondrial transport chain<sup>58</sup>. ROS, in turn, can disrupt epithelial barrier function. Specifically, it has been reported that, in polarized airway epithelial cells, poly I:C (a synthetic mimic of dsRNA) signals through a recently discovered cytosolic dsRNA receptor Nod-like receptor X-1 (NLRX-1) and stimulate NADPH oxidase 1 (NOX-1) and mitochondrial ROS production to cause reactive oxygen species (ROS)

dependent epithelial barrier function disruption<sup>103</sup>. A poly I:C challenge also disrupted endothelial barrier function by causing downregulation of the mRNA for claudin-5, a key endothelial tight junction protein. The exact mechanism is unknown but appears to involve a TLR3-TRIF-NF- $\kappa$ B signaling pathway<sup>104</sup>.

Bacterial RNA engagement with host cell RNA sensors to induce reactive oxygen production can lead to dispersion and dissemination of bacterial biofilm cells. For example, bronchial epithelial cells have been shown to express dual oxidase 2 (Duox2) in response to poly I:C and IFN- $\gamma$  treatment<sup>105</sup>. Duox2 is located in the plasma membrane and can secrete H<sub>2</sub>O<sub>2</sub> directly into the extracellular milieu<sup>106</sup>. Biofilm bacteria, when exposed to oxidative stress, can initiate a dispersal response<sup>107</sup> to release free-swimming planktonic bacteria. Whilst induction of H<sub>2</sub>O<sub>2</sub> production as an immune response can be viewed as a negative event for bacteria, both biofilm-associated and planktonic bacteria express antioxidant enzymes to resist H<sub>2</sub>O<sub>2</sub> killing<sup>108</sup>. Additionally, planktonic bacteria dispersed from biofilms are often as resistant to killing by antimicrobials as their biofilm counterparts<sup>109</sup>. An example of how this process can lead to worsening of clinical outcomes can be found in cystic fibrosis patients with chronic *Pseudomonas aeruginosa* infections. It has been reported in this setting that a viral infection causing mild oxidative stress via activation of Duox 2 leads to dispersal of planktonic bacteria from established lung biofilms, increased transmigration of planktonic bacteria from the apical to basolateral surface of mucociliary-differentiated airway epithelial cells, increased planktonic bacterial and therefore the acute symptom burden<sup>110</sup>.

In an infection, the RNA of pathogenic bacteria may subtly manipulate the host innate immune response to activate inappropriate defense responses that can ultimately favour bacterial survival. In other instances, bacterial mechanisms for disguising their RNA using post-transcriptional modifications can become of importance<sup>79, 85, 86</sup>. Bacteria can also use non-RNA virulence factors to interfere with signaling cascades downstream of RNA-sensors. An example of this was recently reported that showed production of IFN- $\beta$  induced by TLR8-mediated sensing of *S. aureus* ssRNA, is antagonized by TLR2 signaling activated by *S. aureus* lipoproteins<sup>111</sup>. Future detailed investigations of the molecular interactions between bacteria and innate

immunity that involve bacterial RNA may eventually provide a better understanding of what stimulates a productive immune response and identify opportunities for developing novel therapeutic strategies. Overall, these findings confirm that detection of bacterial RNA by the innate immune system is not always as simple as an immune surveillance 'hit' leading to responses that eliminate bacterial pathogens.

#### 4. Sequence-specific action of bacterial RNA in host cells

Bacterial RNA is seemingly not just a ligand for sequence-independent RNA receptors, but is starting to be appreciated for its potential to act in a sequence-specific manner to regulate gene expression at the post-transcriptional level. It is estimated that ~60% of the human protein coding genes could be subject to regulation by their regulatory miRNAs<sup>112</sup> offering a large target for bacteria to manipulate host cells to their advantage using the same endogenous RNA-inhibition (RNAi) machinery. The use of RNA as an effector molecule by directly targeting host RNA may offer the advantages of suppressing the expression of mediators of immunity before they can exert any antibacterial effects i.e. prior to the production of the protein effector itself.

It is interesting to speculate on how a bacterial pathogen's RNA might regulate the host in a sequence-specific manner. The first question to ask is whether a bacterial RNA could bind to a host mRNA? There are differences in the specific mechanisms of action of known non-coding RNAs between human and bacterial cells, and RNA regulation in the eukaryotic host is substantially more complex<sup>113</sup>, but there are several commonalities. Specifically, regulation through direct hybridization between the regulator and the target RNA, mediated by complementary base-pairing, is employed by both kingdoms. For example, both bacterial regulatory RNAs and human miRNA are double-stranded which helps to stabilize the RNA molecule and allows correct orientation of the regulator in relation to the potential target mRNA and accessory proteins<sup>114</sup>, such as AGO2 in humans and Hfq in bacteria. Both human and bacterial regulatory RNAs tend to have a single stranded 'seed' region that is devoid of secondary structure<sup>115</sup> to allow perfect antisense binding to

mRNA targets. Additionally, both miRNAs and bacterial small RNAs (sRNAs) can have varied levels of complementarity with their target RNAs, which in combination with the short seed sequence allows the binding of a single miRNA/sRNA with multiple target mRNAs<sup>116</sup>.

The second question to ask is whether naked bacterial RNA could hijack the hosts own protein machinery to allow it to work in a regulatory manner? Interestingly the eukaryotic RNAi machinery appears to have been put together from various prokaryotic sources (the helicase domain of Dicer and AGO from archaea, the RNase domain of Dicer from bacteria, and RNA-dependent RNA polymerase from bacteriophages)<sup>117</sup>. Furthermore, bacterial sRNA-binding Hfq is an ortholog of eukaryotic Lsm proteins<sup>118</sup> which also act as RNA chaperones to aid in splicing and degradation. Preliminary studies also support that exogenous RNA, from viruses<sup>118</sup> and bacteria<sup>25, 119</sup> can bind to host AGO proteins, key proteins in the RNAi machinery.

With laboratory studies being technically challenging and to date limited, the prediction of what targets a bacterial RNA may have relied on computational modelling. These models require many assumptions to be made and as such later wet-lab validation is vital. Most such studies begin by identifying RNA molecules in the non-human organism that could function as a miRNA mimic when transferred into human cells. Such studies have had success in models for cross-kingdom RNA signaling where both organisms have endogenous miRNAs such as the plant *Arabidopsis thaliana* and humans, and the nematode *Heligmosomoides polygyrus* and mice<sup>120, 121</sup>. Bacteria, however, do not have eukaryotic-like miRNA and their known non-coding RNAs range from 40 to 500 nucleotides in length<sup>122</sup>, which is in contrast to the average length of a human miRNA of about 22 nucleotides<sup>123</sup>. It is possible that long bacteria RNAs are processed into functional fragments. Shmaryahu et al.<sup>124</sup> developed a high throughput bioinformatics pipeline, using the assumption of RNA fragmentation, to analyze all genes in a bacterial genome for their potential to produce RNA transcripts with secondary structures containing double-stranded regions that, through processing, could give rise to miRNA-like fragments. An analysis was made of 448 bacterial genomes, identifying on average 15 putative miRNA-like sequences per organism that could bind

human mRNA. The authors validated the *in silico* analyses by synthesizing mimics of three predicted bacterial RNA-derived 'miRNAs' and transfected them into the human HEK293 cell line. The mimics represented a sequence derived from *Arcobacter butzleri* strain RM4018, a close taxonomic relative of *Campylobacter jejuni* and *Helicobacter pylori*<sup>125</sup>, with complementarity for the human DEK oncogene mRNA, a sequence from *Burkholderia vietnamiensis* G4 with complementarity for the transcript variant 2 mRNA of the human tumour suppressor PTPRJ (protein tyrosine phosphatase receptor type J) gene and a putative sequence from *Burkholderia mallei* with complementarity for the human NFKBIL1 (nuclear factor nuclear factor kappa-light-chain-enhancer of activated B cells) mRNA. Following transfection, mRNA levels of the predicted target genes were determined by RT-qPCR as reduced in expression. This study provides support for the hypothesis that bacterial RNA sequences could potentially target human mRNA, however, the study did not investigate if these putative sequences exist in nature or if they could be transferred from bacteria into human cells to function in the predicted manner.

Koeppen et al.<sup>12</sup> came closer to describing a bacteria-to-human RNA communication system by demonstrating natural transfer of endogenous bacterial short RNA species from *Pseudomonas aeruginosa* into human host cells via MVs, whilst also demonstrating a reduction in protein levels of several kinases whose mRNAs were predicted to be targeted by one of the bacterial MV sRNAs. Specifically, Koeppen and co-authors identified that sRNA52320, a 24-nucleotide tRNA fragment, is transferred into human cells upon exposure to MVs and that it decreases translation of MAP3K7 and MAP2K4 (kinases in the LPS-simulated MAPK signaling pathway) with subsequent reduction in MV-induced host cell secretion of IL-8.

Overall, these studies have provided early indications that bacterial RNA could act in human cells in a sequence-specific manner to exert post-transcriptional effects on gene expression. Studies of two model systems *Caenorhabditis elegans* and *Arabidopsis thaliana* have begun to generate interesting hypotheses and scientific debate based on the biology of RNA in the interactions of *C. elegans* with dietary *E. coli* and *A. thaliana* with the mould *Botrytis cinerea*. However, some caution in the interpretation is required here as these two hosts

have systems to allow signal amplification of exogenous RNA via RNA-dependent polymerases<sup>126, 127</sup>. This mechanism, overcomes a potentially contentious issue in the bacteria-to-human signaling field, concerning whether the amount of bacterial RNA transferred is enough to have a function in the host cells.

Alterations in physiological functions were observed in *C. elegans* fed with *E. coli* overexpressing the non-coding RNAs OxyS (an oxidative stress response regulator) and DsrA (an acid stress response regulator)<sup>128</sup>. In bacteria overexpressing OxyS, a negative foraging effect was observed in the nematodes, which preferred to feed on *E. coli* not over-expressing OxyS when given a choice. The nematodes did not exhibit the repulsion effect when only fed with the OxyS over-expressing strain. Computational analysis of the *C. elegans* genome identified the *che-2* chemosensory gene as a possible target for a sequence-specific interaction with OxyS. Down regulation of CHE-2-GFP fusion expression was visibly seen in *C. elegans* fed on the OxyS over-expressing strain when compared to wild type K12 *E. coli* controls.

Interpretation of these results above led the authors to a hypothesis of environmental RNAi, with OxyS from the diet bacteria suppressing the ability of *C. elegans* to find them. It was shown that the transferred OxyS required the host RNAi pathway, specifically proteins ALG-1 and RDE-4, to function to repress the target CHE-2 protein<sup>128</sup>. The fact that other RNAi genes were described as dispensable<sup>128</sup> raised questions regarding the exact biological mechanism eliciting the gene expression changes and behavioural responses observed<sup>129</sup> and this second, independent study, was unable to support the findings of the original study. By using small RNA-sequencing they were unable to find evidence of OxyS RNAs in fed *C. elegans* that could capably bind to the 17nt interaction site on the *che-2* target mRNA and were unable to validate regulation of the target mRNA itself<sup>129</sup>. Differences between these two study's findings<sup>128, 129</sup> could in part be explained by the use of different strains of dietary bacteria, and

differences in feeding experiment protocols, such that the role of OxyS RNA might only manifest when the nematode has to make a choice about its food. Further investigations are needed to explain the action of OxyS RNA in *C. elegans*, and the story to date highlights the power we now have with RNA sequencing to test complex sequence-specific cross-kingdom communication hypotheses.

RNA sequencing was also a key technique used to determine the potential role of fungal small RNAs in the infective processes of *B. cinerea* using the model plants *A. thaliana* and *Solanum lycopersicum*<sup>130</sup>. *B. cinerea* sRNAs involved in pathogenicity were identified in infected plants, and a simple bioinformatic approach identified sRNAs with miRNA-like structures that were predicted to suppress 4 genes, by perfect antisense binding, all with roles in plant immunity. Ectopic expression of three of these sRNAs in *A. thaliana* left the plant with an increased susceptibility to infection. Importantly, and unlike the situation with *C. elegans*<sup>129</sup>, the microbial sRNAs were shown to bind to host AGO1 within the RNAi machinery, and *A. thaliana* strains in which AGO1 is mutated exhibit reduced susceptibility to *Botrytis* infection. Finally, they demonstrated that *B. cinerea* Dicer mutants lacking the ability to process sRNAs from longer transposon RNAs were less infective. The challenge now is to identify and explain sequence-specific subversion of a bacterial mammalian host by its prokaryotic pathogen.

## 5. Conclusions

Over the last several years the nascent field of cross-kingdom RNA signaling has undergone significant growth. Immune stimulatory effects of bacterial RNA and the role that they play in eliciting and/or suppressing host protective responses are becoming better understood. The sequence-specific effects of regulatory RNAs add an extra dimension of possibilities for RNA signaling. The corresponding development of RNA sequencing and accompanying bioinformatic pipelines now give us powerful tools

### OPEN QUESTIONS:

- ◆ What are the key bacterial RNAs?
- ◆ How important is the effect of RNA when compared to protein virulence factors?
- ◆ Do bacterial RNAs exert an effect in the same way as miRNA?

to investigate this area further. As a consequence, an appreciation that bacterial RNAs are not just a simple uniform trigger of the non-specific immune system, but rather act as complex multifaceted signals is beginning to emerge. On one side is the differential availability of RNA-recognizing sensors within cells, including in their subcellular localization and the need to distinguish between self and foreign RNA. These define the ability of the host to detect intruding RNA and mount a defensive response. On the other side, bacteria appear to utilize multiple methods for protecting and delivering RNA to the host, ranging from MVs which can deliver their cargo over distance, to the intracellular transfer of pathogen's RNA between host cell compartments. The further coexistence of bacterial RNA with other virulence factors such as lipopolysaccharide<sup>53</sup>, with which they could simultaneously travel, serves to add a potential extra level of complexity to unraveling host/pathogen RNA interactions and effects on inflammatory responses<sup>128, 129</sup>.

To advance knowledge, careful experimental design and data interpretation is required to physiologically model relevant amounts and modes of RNA delivery into human cells. Overall, many important technical and biological questions await answers in the coming years to decipher the messages conveyed to human cells by bacterial RNA. Identification of the human cellular, molecular, and genetic networks that can both interact with, and be manipulated by, bacterial RNA signals offers exciting new research directions in the study of bacterial pathogenesis.

### Acknowledgments

The authors are grateful to Priscila Dauros-Singorenko, Jiwon Hong, Anita Muthukaruppan, Vanessa Chang, Kathryn Askelund, Peter Tsai and Cris Print for stimulating discussions that helped form the ideas expressed in this review. We apologize to the authors whose work we were not able to directly cite due to space limitations.

Research by the authors was funded by grants received from the following: Lottery Health Research (NZ), Health Research Council (NZ), Maurice Wilkins Centre for Biodiscovery (NZ), Maurice and Phyllis Paykel Trust (NZ), Ministry of Business, Innovation and Employment (NZ), Johnson and Johnson Surgical Research Fellowship (NZ). These funding entities had no role in the decision to publish or preparation of the manuscript.

### Conflicts of interest

The authors declare that there are no conflicts of interest.

### References

1. Sharp GWG, Hynie S. Stimulation of Intestinal Adenyl Cyclase by Cholera Toxin. *Nature* 1971;229:266–9. doi:10.1038/229266a0.
2. Agbor TA, McCormick BA. Salmonella effectors: important players modulating host cell function during infection. *Cell Microbiol* 2011;13:1858–69. doi:10.1111/j.1462-5822.2011.01701.x.
3. Fuqua WC, Winans SC, Greenberg EP. Quorum sensing in bacteria: the LuxR-LuxI family of cell density-responsive transcriptional regulators. *J Bacteriol* 1994;176:269–75. doi:10.1128/jb.176.2.269-275.1994.
4. Rajput A, Kaur K, Kumar M. SigMol: repertoire of quorum sensing signaling molecules in prokaryotes. *Nucleic Acids Res* 2016;44:D634–9. doi:10.1093/nar/gkv1076.
5. Telford G, Wheeler D, Williams P, Tomkins PT, Appleby P, Sewell H, et al. The *Pseudomonas aeruginosa* Quorum-Sensing Signal Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone Has Immunomodulatory Activity. *Infect Immun* 1998; 66:36–42.
6. Williams P. Quorum sensing, communication and cross-kingdom signalling in the bacterial world. *Microbiology* 2007;153:3923–38. doi:10.1099/mic.0.2007/012856-0.
7. Hughes DT, Sperandio V. Inter-kingdom signalling: communication between bacteria and their hosts. *Nat Rev Microbiol* 2008;6:111–20. doi:10.1038/nrmicro1836.
8. Pfeffer S. Identification of Virus-Encoded MicroRNAs. *Science* 2004;304:734–6. doi:10.1126/science.1096781.
9. Cullen BR. Viruses and microRNAs: RISCy interactions with serious consequences. *Genes Dev* 2011;25:1881–94. doi:10.1101/gad.17352611.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007;9:654–9.
11. Eigenbrod T, Dalpke AH. Bacterial RNA: An Underestimated Stimulus for Innate Immune Responses. *J Immunol* 2015;195:411–8. doi:10.4049/jimmunol.1500530.
12. Koeppen K, Hampton TH, Jarek M, Scharfe M, Gerber SA, Mielcarz DW, et al. A Novel Mechanism of Host-Pathogen Interaction through sRNA in Bacterial Outer Membrane Vesicles. *PLOS Pathog* 2016;12:e1005672. doi:10.1371/journal.ppat.1005672.

13. Blenkinsop C, Simonov D, Muthukaruppan A, Tsai P, Dauros P, Green S, et al. Uropathogenic *Escherichia coli* Releases Extracellular Vesicles That Are Associated with RNA. *PLoS One* 2016;11:e0160440. doi:10.1371/journal.pone.0160440.
14. Deshmukh SD, Kremer B, Freudenberg M, Bauer S, Golenbock DT, Henneke P. Macrophages recognize streptococci through bacterial single-stranded RNA. *EMBO Rep* 2011;12:71–6. doi:10.1038/embor.2010.189.
15. Mancuso G, Gambuzza M, Midiri A, Biondo C, Papasergi S, Akira S, et al. Bacterial recognition by TLR7 in the lysosomes of conventional dendritic cells. *Nat Immunol* 2009;10:587–94. doi:10.1038/ni.1733.
16. Spencer JD, Schwaderer AL, Wang H, Bartz J, Kline J, Eichler T, et al. Ribonuclease 7, an antimicrobial peptide upregulated during infection, contributes to microbial defense of the human urinary tract. *Kidney Int* 2013;83:615–25. doi:10.1038/ki.2012.410.
17. Becknell B, Eichler TE, Beceiro S, Li B, Easterling RS, Carpenter AR, et al. Ribonucleases 6 and 7 have antimicrobial function in the human and murine urinary tract. *Kidney Int* 2015;87:151–61. doi:10.1038/ki.2014.268.
18. Harder J. RNase 7, a Novel Innate Immune Defense Antimicrobial Protein of Healthy Human Skin. *J Biol Chem* 2002;277:46779–84. doi:10.1074/jbc.M207587200.
19. Reithmayer K, Meyer KC, Kleditzsch P, Tiede S, Uppalapati SK, Gläser R, et al. Human hair follicle epithelium has an antimicrobial defence system that includes the inducible antimicrobial peptide psoriasin (S100A7) and RNase 7. *Br J Dermatol* 2009;161:78–89. doi:10.1111/j.1365-2133.2009.09154.x.
20. Kamm RC, Smith AG. Ribonuclease activity in human plasma. *Clin Biochem* 1972;5:198–200. doi:10.1016/S0009-9120(72)80033-X.
21. Blank A, Dekker CA. Ribonucleases of human serum, urine, cerebrospinal fluid, and leukocytes. Activity staining following electrophoresis in sodium dodecyl sulfate-polyacrylamide gels. *Biochemistry* 1981;20:2261–7. doi:10.1021/bi00511a030.
22. Brencicova E, Diebold SS. Nucleic acids and endosomal pattern recognition: how to tell friend from foe? *Front Cell Infect Microbiol* 2013;3:37. doi:10.3389/fcimb.2013.00037.
23. Creemers EE, Tijssen AJ, Pinto YM. Circulating MicroRNAs: Novel biomarkers and extracellular communicators in cardiovascular disease? *Circ Res* 2012;110:483–95. doi:10.1161/CIRCRESAHA.111.247452.
24. Kieft JS, Rabe JL, Chapman EG. New hypotheses derived from the structure of a flaviviral Xrn1-resistant RNA: Conservation, folding, and host adaptation. *RNA Biol* 2015;12:1169–77. doi:10.1080/15476286.2015.1094599.
25. Wang K, Li H, Yuan Y, Etheridge A, Zhou Y, Huang D, et al. The Complex Exogenous RNA Spectra in Human Plasma: An Interface with Human Gut Biota? *PLoS One* 2012;7. doi:10.1371/journal.pone.0051009.
26. Semenov D V., Baryakin DN, Brenner E V., Kurilshikov AM, Vasiliev G V., Bryzgalov L a., et al. Unbiased approach to profile the variety of small non-coding RNA of human blood plasma with massively parallel sequencing technology. *Expert Opin Biol Ther* 2012;12:S43–51. doi:10.1517/14712598.2012.679653.
27. Beatty M, Guduric-Fuchs J, Brown E, Bridgett S, Chakravarthy U, Hogg RE, et al. Small RNAs from plants, bacteria and fungi within the order Hypocreales are ubiquitous in human plasma. *BMC Genomics* 2014;15:933. doi:10.1186/1471-2164-15-933.
28. Leung RK-K, Wu Y-K. Circulating microbial RNA and health. *Sci Rep* 2015;5:16814. doi:10.1038/srep16814.
29. Freedman JE, Gerstein M, Mick E, Rozowsky J, Levy D, Kitchen R, et al. Diverse human extracellular RNAs are widely detected in human plasma. *Nat Commun* 2016;7:11106. doi:10.1038/ncomms11106.
30. Lee P, Tan KS. *Fusobacterium nucleatum* activates the immune response through retinoic acid-inducible gene I. *J Dent Res* 2014;93:162–8. doi:10.1177/0022034513516346.
31. Ghosal A, Upadhyaya BB, Heintz-buschart A, Desai S, Yusuf D, Huang D, et al. The extracellular RNA complement of *Escherichia coli* 2015. doi:10.1002/mbo3.235.
32. Obregón-Henao A, Duque-Correa M a., Rojas M, García LF, Brennan PJ, Ortiz BL, et al. Stable extracellular RNA fragments of mycobacterium tuberculosis induce early apoptosis in human monocytes via a Caspase-8 dependent mechanism. *PLoS One* 2012;7. doi:10.1371/journal.pone.0029970.
33. Ho M-H, Chen C-H, Goodwin JS, Wang B-Y, Xie H. Functional Advantages of *Porphyromonas gingivalis* Vesicles. *PLoS One* 2015;10:e0123448. doi:10.1371/journal.pone.0123448.
34. Sjöström AE, Sandblad L, Uhlin BE, Wai SN. Membrane vesicle-mediated release of bacterial RNA. *Nat Publ Gr* 2015:1–10. doi:10.1038/srep15329.
35. Turnbull L, Toyofuku M, Hynen AL, Kurosawa M, Pessi G, Petty NK, et al. Explosive cell lysis as a mechanism for the biogenesis of bacterial membrane vesicles and biofilms. *Nat Commun* 2016;7:11220. doi:10.1038/ncomms11220.

36. Brown L, Wolf JM, Prados-rosales R, Casadevall A. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi. *Nat Publ Gr* 2015;13:620–30. doi:10.1038/nrmicro3480.
37. Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. *Nat Rev Microbiol* 2015;13:605–19. doi:10.1038/nrmicro3525.
38. Kim JH, Lee J, Park J, Ghoo YS. Gram-negative and Gram-positive bacterial extracellular vesicles. *Semin Cell Dev Biol* 2015;40:97–104. doi:10.1016/j.semcdb.2015.02.006.
39. Pathirana R, Kaparakis-Liaskos M. Bacterial membrane vesicles: biogenesis, immune regulation and pathogenesis. *Cell Microbiol* 2016;1–12. doi:10.1111/cmi.12658.
40. Laughlin RC, Alaniz RC. Outer membrane vesicles in service as protein shuttles, biotic defenders, and immunological doppelgangers. *Gut Microbes* 2016;7:1–5. doi:10.1080/19490976.2016.1222345.
41. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol* 2007;9:654–9. doi:10.1038/ncb1596.
42. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM. Exosomes: Fit to deliver small RNA. *Commun Integr Biol* 2010;3:447–50. doi:10.4161/cib.3.5.12339.
43. Pegtel DM, Cosmopoulos K, Thorley-Lawson D a, van Eijndhoven M a J, Hopmans ES, Lindenberg JL, et al. Functional delivery of viral miRNAs via exosomes. *Proc Natl Acad Sci* 2010;107:6328–33. doi:10.1073/pnas.0914843107.
44. Kulp A, Kuehn MJ. Biological Functions and Biogenesis of Secreted Bacterial Outer Membrane Vesicles. *Annu Rev Microbiol* 2010;64:163–84. doi:10.1146/annurev.micro.091208.073413.
45. Schertzer JW, Whiteley M. A Bilayer-Couple Model of Bacterial Outer Membrane Vesicle Biogenesis. *mBio* 2012;3. doi:10.1128/mBio.00297-11.
46. Roier S, Zingl FG, Cakar F, Durakovic S, Kohl P, Eichmann TO, et al. A novel mechanism for the biogenesis of outer membrane vesicles in Gram-negative bacteria. *Nat Commun* 2016;7:10515. doi:10.1038/ncomms10515.
47. Bayles KW. Bacterial programmed cell death: making sense of a paradox. *Nat Rev Microbiol* 2013;12:63–9. doi:10.1038/nrmicro3136.
48. Bomberger JM, MacEachran DP, Coutermarsh B a., Ye S, O’Toole G a., Stanton B a. Long-distance delivery of bacterial virulence factors by *Pseudomonas aeruginosa* outer membrane vesicles. *PLoS Pathog* 2009;5. doi:10.1371/journal.ppat.1000382.
49. Bielaszewska M, Rüter C, Kunsmann L, Greune L, Bauwens A, Zhang W, et al. Enterohemorrhagic *Escherichia coli* Hemolysin Employs Outer Membrane Vesicles to Target Mitochondria and Cause Endothelial and Epithelial Apoptosis. *PLoS Pathog* 2013;9:1–30. doi:10.1371/journal.ppat.1003797.
50. Kaparakis M, Turnbull L, Carneiro L, Firth S, Coleman HA, Parkington HC, et al. Bacterial membrane vesicles deliver peptidoglycan to NOD1 in epithelial cells. *Cell Microbiol* 2010;12:372–85. doi:10.1111/j.1462-5822.2009.01404.x.
51. Mondal A, Tapader R, Chatterjee NS, Ghosh A, Sinha R, Koley H, et al. Cytotoxic and Inflammatory responses induced by Outer Membrane Vesicles-associated biologically active Proteases from *Vibrio cholerae*. *Infect Immun* 2016;84:IAI.01365-15. doi:10.1128/IAI.01365-15.
52. Olofsson A, Skalmann LN, Obi I, Lundmark R, Arnqvist A. Uptake of *Helicobacter pylori* vesicles is facilitated by clathrin-dependent and clathrin-independent endocytic pathways. *MBio* 2014;5:1–12. doi:10.1128/mBio.00979-14.
53. Parker H, Chitcholtan K, Hampton MB, Keenan JJ. Uptake of *Helicobacter pylori* outer membrane vesicles by gastric epithelial cells. *Infect Immun* 2010;78:5054–61. doi:10.1128/IAI.00299-10.
54. Pollak CN, Delpino MV, Fossati CA, Baldi PC. Outer Membrane Vesicles from *Brucella abortus* Promote Bacterial Internalization by Human Monocytes and Modulate Their Innate Immune Response 2012;7. doi:10.1371/journal.pone.0050214.
55. Thay B, Damm A, Kufer TA, Wai SN, Oscarsson J. *Aggregatibacter actinomycetemcomitans* outer membrane vesicles are internalized in human host cells and trigger NOD1- and NOD2-dependent NF- $\kappa$ B activation. *Infect Immun* 2014;82:4034–46. doi:10.1128/IAI.01980-14.
56. Kunsmann L, Rüter C, Bauwens A, Greune L, Glüder M, Kemper B, et al. Virulence from vesicles: Novel mechanisms of host cell injury by *Escherichia coli* O104:H4 outbreak strain. *Sci Rep* 2015;5:13252. doi:10.1038/srep13252.
57. Sha W, Mitoma H, Hanabuchi S, Bao M, Weng L, Sugimoto N, et al. Human NLRP3 inflammasome senses multiple types of bacterial RNAs. *Proc Natl Acad Sci* 2014;111:16059–64. doi:10.1073/pnas.1412487111.
58. Eigenbrod T, Franchi L, Muñoz-Planillo R, Kirschning CJ, Freudenberg M a, Núñez G, et al. Bacterial RNA mediates activation of caspase-1 and IL-1 $\beta$  release independently of TLRs 3, 7, 9 and TRIF but is dependent on UNC93B. *J Immunol* 2012;189:328–36. doi:10.4049/jimmunol.1103258.

59. Hagmann CA, Herzner AM, Abdullah Z, Zillinger T, Jakobs C, Schuberth C, et al. RIG-I Detects Triphosphorylated RNA of *Listeria monocytogenes* during Infection in Non-Immune Cells 2013;8:1–11. doi:10.1371/journal.pone.0062872.
60. Hagmann CA, Herzner a. M, Abdullah Z, Zillinger T, Jakobs C, Schuberth C, et al. RIG-I Detects Triphosphorylated RNA of *Listeria monocytogenes* during Infection in Non-Immune Cells. PLoS One 2013;8:1–11. doi:10.1371/journal.pone.0062872.
61. Cervantes JL, Vake CJ La, Weinerman B, Luu S, O'Connell C, Verardi PH, et al. Human TLR8 is activated upon recognition of *Borrelia burgdorferi* RNA in the phagosome of human monocytes. J Leukoc Biol 2013;94:1231–41. doi:10.1189/jlb.0413206.
62. Sander LE, Davis MJ, Boekschoten M V, Amsen D, Dascher CC, Ryffel B, et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 2011;474:385–9. doi:10.1038/nature10072.
63. Gupta R, Ghosh S, Monks B, DeOliveira RB, Tzeng TC, Kalantari P, et al. RNA and  $\beta$ -hemolysin of group B *Streptococcus* induce interleukin-1 $\beta$  (IL-1 $\beta$ ) by activating NLRP3 inflammasomes in mouse macrophages. J Biol Chem 2014;289:13701–5. doi:10.1074/jbc.C114.548982.
64. Gupta R, Ghosh S, Monks B, Deoliveira R, Tzeng T, Kalantari P, et al. RNA and  $\beta$ -hemolysin of Group B streptococcus induce IL-1 $\beta$  by activating NLRP3 inflammasomes in mouse macrophages. J Biol Chem 2014:0–11. doi:10.1074/jbc.C114.548982.
65. Kailasan Vanaja S, Rathinam VAK, Atianand MK, Kalantari P, Skehan B, Fitzgerald KA, et al. Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome. Proc Natl Acad Sci U S A 2014;111:7765–70. doi:10.1073/pnas.1400075111.
66. Cervantes JL, La Vake CJ, Weinerman B, Luu S, O'Connell C, Verardi PH, et al. Human TLR8 is activated upon recognition of *Borrelia burgdorferi* RNA in the phagosome of human monocytes. J Leukoc Biol 2013;94:1231–41. doi:10.1189/jlb.0413206.
67. Eigenbrod T, Pelka K, Latz E, Kreikemeyer B, Dalpke AH. TLR8 Senses Bacterial RNA in Human Monocytes and Plays a Nonredundant Role for Recognition of *Streptococcus pyogenes*. J Immunol 2015;195:1092–9. doi:10.4049/jimmunol.1403173.
68. Leonard JN, Ghirlando R, Askins J, Bell JK, Margulies DH, Davies DR, et al. The TLR3 signaling complex forms by cooperative receptor dimerization. Proc Natl Acad Sci 2008;105:258–63. doi:10.1073/pnas.0710779105.
69. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529–31. doi:10.1126/science.1093616.
70. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526–9. doi:10.1126/science.1093620.
71. Geyer M, Pelka K, Latz E. Synergistic activation of Toll-like receptor 8 by two RNA degradation products. Nat Struct Mol Biol 2015;22:99–101. doi:10.1038/nsmb.2967.
72. Nishibayashi R, Inoue R, Harada Y, Watanabe T, Makioka Y, Ushida K. RNA of *Enterococcus faecalis* Strain EC-12 Is a Major Component Inducing Interleukin-12 Production from Human Monocytic Cells. PLoS One 2015;10:e0129806. doi:10.1371/journal.pone.0129806.
73. Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol 2015;32:48–53. doi:10.1016/j.coi.2014.12.012.
74. Kanneganti T-D, Ozören N, Body-Malapel M, Amer A, Park J-H, Franchi L, et al. Bacterial RNA and small antiviral compounds activate caspase-1 through cryopyrin/Nalp3. Nature 2006;440:233–6. doi:10.1038/nature04517.
75. Kailasan Vanaja S, Rathinam VAK, Atianand MK, Kalantari P, Skehan B, Fitzgerald KA, et al. Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome. Proc Natl Acad Sci U S A 2014;111:7765–70. doi:10.1073/pnas.1400075111.
76. Jo E-K, Kim JK, Shin D-M, Sasakawa C. Molecular mechanisms regulating NLRP3 inflammasome activation. Cell Mol Immunol 2016;13:148–59. doi:10.1038/cmi.2015.95.
77. Love AC, Schwartz I, Petzke MM. *Borrelia burgdorferi* RNA induces type I and III interferons via toll-like receptor 7 and contributes to production of NF- $\kappa$ B-dependent cytokines. Infect Immun 2014;82:2405–16. doi:10.1128/IAI.01617-14.
78. Gratz N, Hartweger H, Matt U, Kratochvill F, Janos M, Sigel S, et al. Type I Interferon Production Induced By *Streptococcus Pyogenes*-Derived Nucleic Acids is Required for Host Protection. PLoS Pathog 2011;7:1–16. doi:10.1371/journal.ppat.1001345.
79. Gehrig S, Eberle M-E, Botschen F, Rimbach K, Eberle F, Eigenbrod T, et al. Identification of modifications in microbial, native tRNA that suppress immunostimulatory activity. J Exp Med 2012;209:225–33. doi:10.1084/jem.20111044.
80. Eberle F, Sirin M, Binder M, Dalpke AH. Bacterial RNA is recognized by different sets of immunoreceptors. Eur J Immunol 2009;39:2537–47. doi:10.1002/eji.200838978.
81. Karikó K, Buckstein M, Ni H, Weissman D. Suppression of RNA recognition by Toll-like

- receptors: The impact of nucleoside modification and the evolutionary origin of RNA. *Immunity* 2005;23:165–75. doi:10.1016/j.immuni.2005.06.008.
82. Koski GK, Kariko K, Xu S, Weissman D, Cohen P a, Czerniecki BJ. Cutting Edge: Innate Immune System Discriminates between RNA Containing Bacterial versus Eukaryotic Structural Features That Prime for High-Level IL-12 Secretion by Dendritic Cells. *J Immunol* 2004;172:3989–93. doi:10.4049/jimmunol.172.7.3989.
  83. Eigenbrod T, Dalpke AH. Bacterial RNA: An Underestimated Stimulus for Innate Immune Responses. *J Immunol* 2015;195:411–8. doi:10.4049/jimmunol.1500530.
  84. Kaiser S, Rimbach K, Eigenbrod T, Dalpke AH, Helm M. A modified dinucleotide motif specifies tRNA recognition by TLR7. *RNA* 2014;1351–5. doi:10.1261/rna.044024.113.
  85. Jung S, Von Thülen T, Laukemper V, Pigisch S, Hangel D, Wagner H, et al. A single naturally occurring 2'-O-methylation converts a TLR7- and TLR8-activating RNA into a TLR8-specific ligand. *PLoS One* 2015;10:1–10. doi:10.1371/journal.pone.0120498.
  86. Jöckel S, Nees G, Sommer R, Zhao Y, Cherkasov D, Hori H, et al. The 2'-O-methylation status of a single guanosine controls transfer RNA-mediated Toll-like receptor 7 activation or inhibition. *J Exp Med* 2012;209:235–41. doi:10.1084/jem.20111075.
  87. Abdullah Z, Schlee M, Roth S, Mraheil MA, Barchet W, Böttcher J, et al. RIG-I detects infection with live *Listeria* by sensing secreted bacterial nucleic acids. *EMBO J* 2012;31:4153–64. doi:10.1038/emboj.2012.274.
  88. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. *J Clin Invest* 2009;119:1910–20. doi:10.1172/JCI35412.
  89. Pfeiffer JK, Virgin HW. Transkingdom control of viral infection and immunity in the mammalian intestine. *Science* (80- ) 2016;351:aad5872-aad5872. doi:10.1126/science.aad5872.
  90. Vignola MJ, Kashatus DF, Taylor GA, Counter CM, Valdivia RH. cPLA2 regulates the expression of type I interferons and intracellular immunity to *Chlamydia trachomatis*. *J Biol Chem* 2010;285:21625–35. doi:10.1074/jbc.M110.103010.
  91. Owen KA, Anderson CJ, Casanova JE. Salmonella suppresses the TRIF-dependent type I interferon response in macrophages. *MBio* 2016;7:1–15. doi:10.1128/mBio.02051-15.
  92. Sionov E, Mayer-Barber KD, Chang YC, Kauffman KD, Eckhaus MA, Salazar AM, et al. Type I IFN Induction via Poly-ICLC Protects Mice against Cryptococcosis. *PLoS Pathog* 2015;11:1–19. doi:10.1371/journal.ppat.1005040.
  93. Mancuso G, Midiri a., Biondo C, Beninati C, Zummo S, Galbo R, et al. Type I IFN Signaling Is Crucial for Host Resistance against Different Species of Pathogenic Bacteria. *J Immunol* 2007;178:3126–33. doi:10.4049/jimmunol.178.5.3126.
  94. Malireddi RKS, Kanneganti T-D. Role of type I interferons in inflammasome activation, cell death, and disease during microbial infection. *Front Cell Infect Microbiol* 2013;3:77. doi:10.3389/fcimb.2013.00077.
  95. Rayamajhi M, Humann J, Kearney S, Hill KK, Lenz LL. Antagonistic crosstalk between type I and II interferons and increased host susceptibility to bacterial infections. *Virulence* 2010;1:418–22. doi:10.4161/viru.1.5.12787.
  96. Wiens KE, Ernst JD. The Mechanism for Type I Interferon Induction by *Mycobacterium tuberculosis* is Bacterial Strain-Dependent. *PLoS Pathog* 2016;12:1–20. doi:10.1371/journal.ppat.1005809.
  97. Petzke MM, Iyer R, Love AC, Spieler Z, Brooks A, Schwartz I. *Borrelia burgdorferi* induces a type I interferon response during early stages of disseminated infection in mice. *BMC Microbiol* 2016;16:29. doi:10.1186/s12866-016-0644-4.
  98. D'Elia et al. T-cell response to bacterial agents. *J Infect Dev Ctries* 2011;5:640–5. doi:10.3855/jidc.2019.
  99. Liang SC, Tan X-Y, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. *J Exp Med* 2006;203:2271–9. doi:10.1084/jem.20061308.
  100. Lee B, Robinson KM, McHugh KJ, Scheller E V, Mandalapu S, Chen C, et al. Influenza-induced Type I Interferon Enhances Susceptibility to Gram-negative and Gram-positive Bacterial Pneumonia in Mice. *Am J Physiol Lung Cell Mol Physiol* 2015;ajplung.00338.2014. doi:10.1152/ajplung.00338.2014.
  101. Kudva A, Scheller E V, Robinson KM, Crowe CR, Choi SM, Slight SR, et al. Influenza A Inhibits Th17-Mediated Host Defense against Bacterial Pneumonia in Mice. *J Immunol* 2011;186:1666–74. doi:10.4049/jimmunol.1002194.
  102. Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary *Streptococcus pneumoniae* infection by negative regulation of  $\gamma\delta$  T cells. *J Virol* 2012;86:12304–12. doi:10.1128/JVI.01269-12.
  103. Unger BL, Ganesan S, Comstock AT, Faris AN, Hershenson MB, Sajjan US. Nod-like receptor X-1 is required for rhinovirus-induced barrier dysfunction in airway epithelial cells. *J Virol* 2014;88:3705–18. doi:10.1128/JVI.03039-13.

104. Huang L-Y, Stuart C, Takeda K, D'Agnillo F, Golding B, Morita K, et al. Poly(I:C) Induces Human Lung Endothelial Barrier Dysfunction by Disrupting Tight Junction Expression of Claudin-5. *PLoS One* 2016;11:e0160875. doi:10.1371/journal.pone.0160875.
105. Harper RW, Xu C, Eiserich JP, Chen Y, Kao CY, Thai P, et al. Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cytokines in respiratory tract epithelium. *FEBS Lett* 2005;579:4911–7. doi:10.1016/j.febslet.2005.08.002.
106. Geiszt M. Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense. *FASEB J* 2003;17:1502–4. doi:10.1096/fj.02-1104fje.
107. Barraud N, Hassett DJ, Hwang S-H, Rice SA, Kjelleberg S, Webb JS. Involvement of Nitric Oxide in Biofilm Dispersal of *Pseudomonas aeruginosa*. *J Bacteriol* 2006;188:7344–53. doi:10.1128/JB.00779-06.
108. Panmanee W, Hassett DJ. Differential roles of OxyR-controlled antioxidant enzymes alkyl hydroperoxide reductase (AhpCF) and catalase (KatB) in the protection of *Pseudomonas aeruginosa* against hydrogen peroxide in biofilm vs. planktonic culture. *FEMS Microbiol Lett* 2009;295:238–44. doi:10.1111/j.1574-6968.2009.01605.x.
109. Spoering AL, Lewis K. Biofilms and Planktonic Cells of *Pseudomonas aeruginosa* Have Similar Resistance to Killing by Antimicrobials. *J Bacteriol* 2001;183:6746–51. doi:10.1128/JB.183.23.6746-6751.2001.
110. Chattoraj SS, Ganesan S, Jones AM, Helm JM, Comstock AT, Bright-Thomas R, et al. Rhinovirus infection liberates planktonic bacteria from biofilm and increases chemokine responses in cystic fibrosis airway epithelial cells. *Thorax* 2011;66:333–9. doi:10.1136/thx.2010.151431.
111. Bergstrom B, Aune MH, Awuh J a., Kojen JF, Blix KJ, Ryan L, et al. TLR8 Senses *Staphylococcus aureus* RNA in Human Primary Monocytes and Macrophages and Induces IFN- Production via a TAK1-IKK -IRF5 Signaling Pathway. *J Immunol* 2015;195:doi:10.4049/jimmunol.1403176.
112. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. *Genome Res* 2008;19:92–105. doi:10.1101/gr.082701.108.
113. Hammond SM. An overview of microRNAs. *Adv Drug Deliv Rev* 2015;87:3–14. doi:10.1016/j.addr.2015.05.001.
114. Ishikawa H, Otaka H, Maki K, Morita T, Aiba H. The functional Hfq-binding module of bacterial sRNAs consists of a double or single hairpin preceded by a U-rich sequence and followed by a 3' poly(U) tail. *RNA* 2012;18:1062–74. doi:10.1261/rna.031575.111.
115. Belter A, Gudanis D, Rolle K, Piwecka M, Gdaniec Z, Naskręć-Barciszewska MZ, et al. Mature miRNAs form secondary structure, which suggests their function beyond RISC. *PLoS One* 2014;9:1–23. doi:10.1371/journal.pone.0113848.
116. Shabalina SA, Spiridonov NA, Kashina A. Sounds of silence: Synonymous nucleotides as a key to biological regulation and complexity. *Nucleic Acids Res* 2013;41:2073–94. doi:10.1093/nar/gks1205.
117. Shabalina S a., Koonin E V. Origins and evolution of eukaryotic RNA interference. *Trends Ecol Evol* 2008;23:578–87. doi:10.1016/j.tree.2008.06.005.
118. Wilusz CJ, Wilusz J. Lsm proteins and Hfq: Life at the 3' end. *RNA Biol* 2013;10:592–601. doi:10.4161/rna.23695.
119. Zhao H, Lii Y, Zhu P, Jin H. Isolation and Profiling of Protein-Associated Small RNAs. In: Jin H, Gassmann W, editors. *RNA Abundance Anal. Methods Protoc.*, Totowa, NJ: Humana Press; 2012, p. 165–76. doi:10.1007/978-1-61779-839-9\_13.
120. Zhang H, Li Y, Liu Y, Liu H, Wang H, Jin W, et al. Role of plant MicroRNA in cross-species regulatory networks of humans. *BMC Syst Biol* 2016;10:60. doi:10.1186/s12918-016-0292-1.
121. Buck AH, Coakley G, Simbari F, McSorley HJ, Quintana JF, Le Bihan T, et al. Exosomes secreted by nematode parasites transfer small RNAs to mammalian cells and modulate innate immunity. *Nat Commun* 2014;5:5488. doi:10.1038/ncomms6488.
122. Lalaouna D, Simoneau-Roy M, Lafontaine D, Massé E. Regulatory RNAs and target mRNA decay in prokaryotes. *Biochim Biophys Acta - Gene Regul Mech* 2013;1829:742–7. doi:10.1016/j.bbagr.2013.02.013.
123. Yates LA, Norbury CJ, Gilbert RJC. The Long and Short of MicroRNA. *Cell* 2013;153:516–9. doi:10.1016/j.cell.2013.04.003.
124. Shmaryahu A, Carrasco M, Valenzuela PDT. Prediction of Bacterial microRNAs and possible targets in human cell transcriptome. *J Microbiol* 2014;52:482–9. doi:10.1007/s12275-014-3658-3.
125. Miller WG, Parker CT, Rubenfield M, Mendz GL, Wösten MMSM, Ussery DW, et al. The complete genome sequence and analysis of the epsilonproteobacterium *Arcobacter butzleri*. *PLoS One* 2007;2. doi:10.1371/journal.pone.0001358.
126. Grishok A. Biology and Mechanisms of Short RNAs in *Caenorhabditis elegans*. *Adv. Genet.*, vol. 83, 2013, p. 1–69. doi:10.1016/B978-0-12-407675-4.00001-8.
127. Tang G. A biochemical framework for RNA silencing in plants. *Genes Dev* 2003;17:49–63. doi:10.1101/gad.1048103.

128. Winston WM, Sutherlin M, Wright AJ, Feinberg EH, Hunter CP. *Caenorhabditis elegans* SID-2 is required for environmental RNA interference. *Proc Natl Acad Sci* 2007;104:10565–70. doi:10.1073/pnas.0611282104.
129. Akay A, Sarkies P, Miska EA. *E. coli* OxyS non-coding RNA does not trigger RNAi in *C. elegans*. *Sci Rep* 2015;5:9597. doi:10.1038/srep09597.
130. Weiberg A, Wang M, Lin F-M, Zhao H, Zhang Z, Kaloshian I, et al. Fungal small RNAs suppress plant immunity by hijacking host RNA interference pathways. *Science* 2013;342:118–23. doi:10.1126/science.1239705.

DISCOVERIES is a peer-reviewed, open access, online, multidisciplinary and integrative journal, publishing high impact and innovative manuscripts from all areas related to MEDICINE, BIOLOGY and CHEMISTRY; © 2016, Applied Systems